⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors

Official Title: Protocol for the Treatment of Extracranial Germ Cell Tumours in Children and Adolescents (GC III)

Study ID: NCT00274950

Study Description

Brief Summary: RATIONALE: Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This phase III trial is studying how well observation and/or combination chemotherapy works after surgery or biopsy in treating young patients with extracranial germ cell tumors.

Detailed Description: OBJECTIVES: * Stratify and reduce treatment for pediatric patients with extracranial germ cell tumors while maintaining event-free survival. * Treat newly diagnosed patients with extracranial germ cell tumors requiring chemotherapy with a carboplatin-based strategy. * Develop a common strategy for the treatment of patients with recurrent or progressive extracranial germ cell tumors. * Register all cases of mature and immature teratoma. * Develop a common strategy for the management of immature and mature teratoma, including follow-up strategies to permit early detection of yolk sac recurrence. OUTLINE: This is a multicenter study. Patients who have not had prior biopsy or surgical resection undergo biopsy (if feasible) or surgical resection. Patients with mature or immature teratoma undergo observation. These patients who relapse (i.e., tumor regrowth) may undergo further surgical resection unless tumor markers are significantly elevated. If the tumor markers are significantly elevated, these patients proceed to JEB chemotherapy according to risk group. Patients with all other malignant germ cell tumors are assigned to 1 of 3 treatment groups according to risk. * Low-risk group: Patients with normal tumor markers undergo observation. Patients with rising tumor markers only AND no imageable tumor proceed to treatment as in the intermediate-risk group. Patients with rising tumor markers AND/OR imageable tumor are considered to have relapsed and proceed to treatment as in the intermediate- or high-risk group. * Intermediate-risk group: Patients receive JEB chemotherapy comprising etoposide IV over 4 hours on days 1-3, carboplatin IV over 1 hour on day 2, and bleomycin IV over 30 minutes on day 3. Treatment repeats every 21 days for 4 courses. Patients with residual tumors after completion of chemotherapy may undergo second-look surgery. * High-risk group: Patients receive JEB chemotherapy as in the intermediate-risk group for 6 courses. Patients with residual tumors after completion of chemotherapy may undergo second-look surgery. * Relapse therapy: Patients in the intermediate- or high-risk group who relapse after completion of JEB chemotherapy receive vinblastine IV on days 1 and 2, ifosfamide IV over 1 hour on days 1-5, and cisplatin IV on days 1-5. Treatment repeats every 21 days for 6 courses. PROJECTED ACCRUAL: A total of 105 patients will be accrued for this study.

Eligibility

Minimum Age:

Eligible Ages: CHILD

Sex: ALL

Healthy Volunteers: No

Locations

Our Lady's Hospital for Sick Children Crumlin, Dublin, , Ireland

Birmingham Children's Hospital, Birmingham, England, United Kingdom

Institute of Child Health at University of Bristol, Bristol, England, United Kingdom

Addenbrooke's Hospital, Cambridge, England, United Kingdom

Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

Leicester Royal Infirmary, Leicester, England, United Kingdom

Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom

Royal London Hospital, London, England, United Kingdom

Great Ormond Street Hospital for Children, London, England, United Kingdom

Royal Manchester Children's Hospital, Manchester, England, United Kingdom

Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom

Queen's Medical Centre, Nottingham, England, United Kingdom

Children's Hospital - Sheffield, Sheffield, England, United Kingdom

Southampton General Hospital, Southampton, England, United Kingdom

Royal Marsden - Surrey, Sutton, England, United Kingdom

Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom

Royal Aberdeen Children's Hospital, Aberdeen, Scotland, United Kingdom

Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom

Royal Hospital for Sick Children, Glasgow, Scotland, United Kingdom

Childrens Hospital for Wales, Cardiff, Wales, United Kingdom

Contact Details

Name: Juliet Hale, MD

Affiliation: Sir James Spence Institute of Child Health at Royal Victoria Infirmary

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: